<DOC>
	<DOCNO>NCT01975714</DOCNO>
	<brief_summary>Bimatoprost 0.03 % preservative free monodose eye drop solution ( BUDPF ) new product compose synthetic prostamide , bimatoprost 0.3 % preservative free formulation . This new product use once-daily topical ocular therapy reduction elevate intraocular pressure ( IOP ) patient open-angle glaucoma , ocular hypertension , sensitive preservative . The individual active component BUDPF , bimatoprost establish therapeutic agent well document IOP efficacy ( 1 ) . Prostamides , bimatoprost , believe low IOP mainly increase uveoscleral outflow . The comparator , Preservative Free Latanoprost 0.005 % Unit Dose ( LUDPF , eg . MonoprostÂ® ) , recently launch number country Europe contain latanoprost new preservative free formulation . It clinically important compare newly enter preservative free product respect tolerability efficacy . A good tolerability combine maximum efficacy reduce burden daily glaucoma therapy provide clear therapeutic benefit glaucoma patient provide enhanced compliance real-world IOP-lowering efficacy . The hypothesis study monodose bimatoprost effective monodose latanoprost least 1 mmHg . ( AIBILI apply unrestricted grant Allergan perform study )</brief_summary>
	<brief_title>Intraocular Pressure Tolerability Study Preservative-free Prostaglandins ( Bimatoprost Latanoprost ) Glaucoma Ocular Hypertension : European , Multicentric , Investigator-led , Single Masked Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Inclusion Criteria include : Ocular hypertension , pseudoexfoliation glaucoma ( XFG ) primary openangle glaucoma ( POAG ) patient preserve prostaglandin monotherapy least 6 week . At prescreening screen visit IOP le equal 21 mm Hg eye . Exclusion Criteria include : Any ocular condition safety concern , visual field defect MD value 12dB , closed/barely open anterior chamber angle history acute angle closure either eye , ocular surgery within past three month either eye ; glaucoma surgery within past 6 month either eye , ocular inflammation/infection occur within three month prior pretrial visit either eye , pigmentary glaucoma neovascular glaucoma either eye , topical ocular medication interfere study medication either eye know hypersensitivity component trial drug solution participation clinical trial , involve investigational drug within one month prior pretrial visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>Preservative-free prostaglandin</keyword>
</DOC>